Core Viewpoint - China Tongfu (01763) announced a commercial cooperation agreement with Novartis Pharma Technology (Zhejiang) Co., Ltd. for the drug Paiweituo® (Lutetium-177-PSMA-617 injection), which is the first and only approved targeted radioligand therapy for advanced prostate cancer in China [1] Group 1: Company Collaboration - The agreement marks the beginning of a strategic partnership between China Tongfu's subsidiary, Atomic High-Tech Co., Ltd., and Novartis, focusing on the innovative nuclear medicine product Paiweituo® [1] - Atomic High-Tech will leverage its years of compliant operation experience in the field of radiopharmaceuticals to collaborate with Novartis, providing customized product supply and solutions for medical institutions and patients [1] Group 2: Product Significance - Paiweituo® aims to offer a new nuclear medicine treatment option that extends life and improves the quality of life for patients with advanced prostate cancer [1]
中国同辐(01763)附属原子高科与诺华公司签署商业合作协议